Alpha Tau Achieves Significant Licensing Milestone
Alpha Tau Medical Ltd. has marked a major step towards commercial readiness by securing a critical radioactive material license. This accomplishment is pivotal as the company prepares to launch its innovative alpha-radiation cancer therapy, Alpha DaRT, which focuses on treating tumors effectively.
Recently, Alpha Tau received this license from the Bureau of Public Health Protection, Radiological Health Section, in New Hampshire. This is an essential milestone for the firm, especially as it looks forward to initiating treatment manufacturing of Alpha DaRT in the upcoming years.
Details of the Manufacturing Facility
In alignment with its growth strategy, Alpha Tau has entered into a long-term lease for more than 14,000 square feet in Hudson, New Hampshire. The facility's construction will occur in multiple phases, which is designed to support the scaling up of Alpha DaRT sources considerably. The initial phase alone aims to accommodate around 400,000 sources for local distribution, showcasing substantial potential for operational expansion.
Uzi Sofer, the CEO of Alpha Tau, expressed enthusiasm about reaching this operational milestone. He acknowledged the hard work of the team, contractors, and regulatory officials that facilitated the licensing process, emphasizing the company's commitment to high standards throughout the facility's development.
Plans for Facility Operations
The receipt of the radioactive material license enables Alpha Tau to move forward with equipping the manufacturing facility. There are plans for verification and validation processes as the team introduces thorium generators, with the target to commence production of the Alpha DaRT treatments during the next operational cycle.
Alpha DaRT is currently undergoing evaluation in a variety of clinical trials focused on treating a broad range of cancers, including skin, head & neck, and lung cancers. This innovative therapy is formulated to deliver potent treatment while minimizing damage to surrounding healthy tissue.
About Alpha Tau Medical Ltd.
Established in 2016, Alpha Tau has positioned itself at the forefront of oncology therapy. The company is dedicated to developing cutting-edge solutions that target solid tumors, particularly through the Alpha DaRT technology developed by esteemed professors at Tel Aviv University. Alpha DaRT utilizes radium-224 sources to achieve effective tumor irradiation, and its unique mechanism is designed to minimize exposure to adjacent healthy tissues, thus enhancing the treatment's efficacy.
Frequently Asked Questions
What is Alpha DaRT?
Alpha DaRT is an innovative cancer therapy developed by Alpha Tau that utilizes alpha radiation to treat solid tumors effectively.
Where is Alpha Tau's manufacturing facility located?
The manufacturing facility is located in Hudson, New Hampshire, and will support the production of Alpha DaRT sources.
What major milestone has Alpha Tau recently achieved?
Alpha Tau has recently secured a radioactive materials license, a significant step towards commercializing its Alpha DaRT therapy.
What is the future plan for Alpha Tau regarding Alpha DaRT production?
Alpha Tau plans to commence production of Alpha DaRT sources during 2026 as part of its operational expansion.
How does Alpha DaRT work?
Alpha DaRT works by delivering alpha-emitting radiation directly to tumors, aiming to destroy cancer cells while sparing surrounding healthy tissue.
